Senseonics’ (SENS) Buy Rating Reiterated at HC Wainwright

Senseonics (NYSE:SENS)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a report issued on Friday,Benzinga reports. They currently have a $2.00 price objective on the stock.

Separately, StockNews.com started coverage on shares of Senseonics in a report on Friday, November 8th. They set a “sell” rating on the stock.

Senseonics Price Performance

Senseonics stock opened at $0.28 on Friday. The company has a market capitalization of $168.13 million, a PE ratio of -2.18 and a beta of 0.79. The company has a current ratio of 2.47, a quick ratio of 2.89 and a debt-to-equity ratio of 59.17. The stock has a 50-day moving average price of $0.35 and a two-hundred day moving average price of $0.40. Senseonics has a 12 month low of $0.28 and a 12 month high of $0.75.

Institutional Trading of Senseonics

Several institutional investors have recently added to or reduced their stakes in the stock. FMR LLC increased its position in shares of Senseonics by 48,267.2% during the third quarter. FMR LLC now owns 168,318 shares of the company’s stock worth $59,000 after buying an additional 167,970 shares during the period. State Board of Administration of Florida Retirement System bought a new stake in Senseonics during the first quarter valued at $91,000. GSA Capital Partners LLP acquired a new stake in Senseonics during the 3rd quarter worth about $117,000. Virtu Financial LLC bought a new position in shares of Senseonics in the 1st quarter worth about $162,000. Finally, Symmetry Partners LLC acquired a new position in shares of Senseonics in the 3rd quarter valued at about $164,000. 12.36% of the stock is currently owned by institutional investors.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.